还原型谷胱甘肽对减轻肝癌化疗氧化应激及肝脏毒性的应用研究

doi:10.3760/cma.j.issn.1007-1245.2023.10.015

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (10): 1400-1403.DOI: 10.3760/cma.j.issn.1007-1245.2023.10.015

还原型谷胱甘肽对减轻肝癌化疗氧化应激及肝脏毒性的应用研究

侯静静郝蕊杨秋敏

商丘市第一人民医院耳鼻喉肿瘤二科，商丘　467000

收稿日期:2022-12-27 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: 侯静静，Email：houjinjingoi@163.com
基金资助:
河南省医学科技攻关项目（LHGJ20210021132）

Reduced glutathione in relieving oxidative stress and hepatotoxicity of chemotherapy for patients with liver cancer

Hou Jingjing, Hao Rui, Yang Qiumin

Second Department of Otorhinolaryngology and Oncology, Shangqiu First People's Hospital, Shangqiu 467000, ChinaChina

Received:2022-12-27 Online:2023-05-15 Published:2023-05-16
Contact: Hou Jingjing, Email: houjinjingoi@163.com
Supported by:
Problem-tackling Project of Medical Science and Technology in Henan (LHGJ20210021132)

摘要/Abstract

摘要：

目的　观察还原型谷胱甘肽（GSH）对减轻肝癌化疗患者氧化应激反应及肝脏毒性的临床效果。方法　本文为前瞻性研究，病例纳入商丘市第一人民医院2020年3月至2021年8月期间收治的103例肝癌患者，采用抽签法将其分为观察组（52例）和对照组（51例）。观察组中男30例、女22例，年龄（60.44±5.25）岁；对照组中男31例、女20例，年龄（61.25±5.47）岁。两组均统一接受化疗，观察组加用GSH辅助化疗，比较两组患者治疗前后的肝功能、氧化应激反应变化情况。治疗后对所有患者开展为期1年随访，比较两组化疗相关并发症发生情况及生存情况。组间比较采用χ²检验、t检验进行统计分析。结果　治疗前，两组患者的肝功能、氧化应激反应指标差异均无统计学意义（均P>0.05）；治疗后，观察组的天冬氨酸转氨酶（AST）为（50.25±5.33）U/L、丙氨酸转氨酶（ALT）为（50.16±5.23）U/L、总胆红素（TBil）水平为（30.22±5.14）μmol/L、丙二醛（MDA）为（4.88±0.24）nmol/L、过氧化氢酶（CAT）为（72.33±5.27）Ku/L，均低于对照组［（53.44±5.17）U/L、（53.11±5.16）U/L、（33.16±5.33）μmol/L、（5.02±0.33）nmol/L、（75.31±5.62）Ku/L］，两组比较，差异均有统计学意义（t=3.082、2.850、2.881、2.466、2.777，均P<0.05）；观察组的超氧化物歧化酶（SOD）为（325.44±10.27）U/L，高于对照组的（319.42±10.36）U/L（t=2.962，P=0.004）。随访期间，观察组的化疗相关并发症发生率为5.77%（3/52），低于对照组19.61%（10/51）（χ²=4.471，P=0.035）；观察组肝癌患者生活质量（QLQ-C30）评分（57.73±5.28）分、生命质量（QLQ-HCC 18）评分（22.47±3.15）分，均低于对照组［（60.12±5.32）分、（24.15±3.44）分］（t=2.288、2.586，P=0.024、0.011）。结论　采用GSH辅助化疗可减轻肝癌患者的氧化应激反应及肝功能损伤，对降低化疗相关并发症发生风险并提升生活质量、生存质量均有积极意义。

关键词:

肝癌, 化疗, 还原型谷胱甘肽, 氧化应激反应, 肝脏毒性

Abstract:

Objective　To observe the clinical effect of reduced glutathione on reducing oxidative stress and hepatotoxicity in patients with liver cancer undergoing chemotherapy. Methods　One hundred and three patients with liver cancer admitted to Shangqiu First People's Hospital from March 2020 to August 2021 were selected for the prospective study. They were divided into an observation group (52 cases) and a control group (51 cases) by drawing lots. In the observation group, there were 30 males and 22 females; they were (60.44±5.25) years old. In the control group, there were 31 males and 20 females; they were (61.25±5.47) years old. Both groups received chemotherapy uniformly. The observation group used reduced glutathione as the adjuvant chemotherapy. The changes of liver function and oxidative stress reaction between the two groups before and after the treatment were compared. All the patients were followed up for one year after the treatment. The incidences of chemotherapy related complications and survival rates were compared between the two groups. The data were compared between these two groups by χ² and t tests. Results　Before the treatment, there were statistical differences in liver function and oxidative stress reaction between the two groups (all P>0.05). After the treatment, the levels of glutamic oxaloacetic transaminase (AST), alanine aminotransferase (ALT), total bilirubin (TBil), malondialdehyde (MDA), and catalase (CAT) in the observation group were lower than those in the control group [(50.25±5.33) U/L vs. (53.44±5.17) U/L, (50.16±5.23) U/L vs. (53.11±5.16) U/L, (30.22±5.14) μmol/L vs. (33.16±5.33) μmol/L, (4.88±0.24) nmol/L vs. (5.02±0.33) nmol/L, and (72.33±5.27) Ku/L vs. (75.31±5.62) Ku/L], with statistical differences (t=3.082, 2.850, 2.881, 2.466, and 2.777; all P<0.05); the level of superoxide dismutase (SOD) in the observation group was higher than that in the control group [(325.44±10.27) U/L vs. (319.42±10.36) U/L; t=2.962, P=0.004]. During the follow-up, the incidence of chemotherapy related complications in the observation group was lower than that in the control group [5.77% (3/52) vs. 19.61% (10/51); χ²=4.471, P=0.035]; the scores of living quality (QLQ-C30) and life quality (QLQ-HCC) in the observation group were lower than those in the control group [(57.73±5.28) vs. (60.12±5.32) and (22.47±3.15) vs. (24.15±3.44); t=2.288 and 2.586, P=0.024 and 0.011]. Conclusion　Reduced glutathione adjuvant chemotherapy can reduce the oxidative stress reaction and liver function damage in patients with liver cancer, and has positive significance in reducing the risk of chemotherapy related complications and improving the living and life qualities.

Key words:

Liver cancer, Chemotherapy, Reduced glutathione, Oxidative stress reaction, Hepatotoxicity

侯静静郝蕊杨秋敏.

还原型谷胱甘肽对减轻肝癌化疗氧化应激及肝脏毒性的应用研究 [J]. 国际医药卫生导报, 2023, 29(10): 1400-1403.

Hou Jingjing, Hao Rui, Yang Qiumin.

Reduced glutathione in relieving oxidative stress and hepatotoxicity of chemotherapy for patients with liver cancer [J]. International Medicine and Health Guidance News, 2023, 29(10): 1400-1403.

参考文献

[1] Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the global burden of disease study 2016 and implications for liver cancer prevention[J]. J Hepatol, 2019,70(4):674-683. DOI: 10.1016/j.jhep.2018.12.001.
[2] 周元敏,彭育立,陈小轲,等.肝动脉栓塞化疗术结合小分子靶向治疗晚期肝癌患者的效果与安全性[J].中国社区医师,2022,38(3):40-42.
[3] 陈帅.肝动脉化疗栓塞术后行经皮射频消融术治疗高危部位原发性肝癌的效果和安全性分析[J].医学理论与实践,2019,32(22):3651-3652.DOI:10.19381/j.issn.1001- 7585.2019.22.034.
[4] 陆一峰.探讨肝动脉介入化疗栓塞术联合还原型谷胱甘肽治疗在老年晚期肝癌患者中的应用效果[J].系统医学,2020,5(21):150-152,155.DOI:10.19368/j.cnki.2096- 1782.2020.21.150.
[5] 林国桢,代天星,刘荣强,等.不同肝功能Child-Pugh分级对肝癌肝移植受者预后的影响[J].器官移植,2019,10(3):308-312.DOI:10.3969/j.issn.1674-7445.2019.03.014.
[6] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].解放军医学杂志,2015,40(11):865-872.DOI:10.11855/j.issn.0577- 7402.2015.11.03.
[7] Vogel A, Qin S, Kudo M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021,6(8):649-658. DOI: 10.1016/S2468-1253(21)00110-2.
[8] Chie WC, Blazeby JM, Hsiao CF, et al. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18[J]. Hepatology, 2012,55(4):1122-1129. DOI: 10.1002/hep.24798.
[9] 林秀强.肝动脉栓塞化疗术联合小分子靶向治疗对晚期肝癌的效果[J].深圳中西医结合杂志,2020,30(1):184-185.DOI:10.16458/j.cnki.1007-0893.2020.01.091.
[10] 董国强,蒋礼,张应战.肝脏恶性肿瘤精细介入治疗前后肝储备功能的评价分析[J].临床医药实践,2022,31(9):646-648,684.DOI:10.16047/j.cnki.cn14-1300/r.2022. 09.019
[11] 吕厚宽,刘晓晖.异甘草酸镁联合还原型谷胱甘肽对肝细胞癌肝切除患者的应用价值[J].中国普通外科杂志,2020,29(4):458-465.DOI:10.7659/j.issn.1005-6947. 2020. 04.009.
[12] 刘东,张罡,沈忠培,等.艾迪注射液联合肝动脉化疗栓塞术对原发性肝癌患者的临床疗效、血管生长因子及细胞免疫功能的影响[J].海南医学院学报,2019,25(23):1770-1775.DOI:10.13210/j.cnki.jhmu.20191118.001.
[13] 高兰,龙世棋,陈博鑫,等.还原型谷胱甘肽靶向氧化应激对肝癌干细胞的作用[J].临床与实验病理学杂志,2020,36(8):887-892.DOI:10.13315/j.cnki.cjcep.2020.08.002.
[14] 赵晓光,史玉洁.应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J].实用肝脏病杂志,2019,22(3):425-428.DOI:10.3969/j.issn. 1672-5069.2019.03.029.
[15] 陈天宇.原发性肝癌介入治疗患者运用还原型谷胱甘肽的效果分析[J].吉林医学,2020,41(4):862-863.DOI:10.3969/j.issn.1004-0412.2020.04.037.

还原型谷胱甘肽对减轻肝癌化疗氧化应激及肝脏毒性的应用研究

Reduced glutathione in relieving oxidative stress and hepatotoxicity of chemotherapy for patients with liver cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	侯静静郝蕊杨秋敏. 头孢他啶注射液辅助肺癌化疗对肺部感染的防治效果分析 [J]. 国际医药卫生导报, 2023, 29(9): 1249-1253.
[2]	李东梅史健齐欣欣. 措施分类护理模式在急性髓系白血病缓解后化疗患者中的应用效果 [J]. 国际医药卫生导报, 2023, 29(9): 1313-1317.
[3]	周亚丹. 围术期预见性护理对肝癌射频消融术患者的影响 [J]. 国际医药卫生导报, 2023, 29(5): 708-713.
[4]	姚宝乐朱晓娟温望文戴伟刘圣兰黄浩. TCF7L2及经典Wnt信号通路在肝癌中作用的研究进展 [J]. 国际医药卫生导报, 2023, 29(2): 149-.